Abstract
Background
Imatinib myselate is a molecularly targeted drug that inhibits Abl tyrosine kinase, as well as type III tyrosine kinase receptors such as platelet-derived growth factor receptor (PDGFR), KIT, colony-stimulating factor 1 receptor (CSF-1R), and discoidin domain receptor (DDR). Ph1 chromosome-positive chronic myeloid leukemias (CMLs), KIT-positive gastrointestinal stromal tumors (GISTs), and PDGFR-positive dermatofibrosarcoma protuberans (DFSP) have been reported to be responsive to imatinib treatment. We conducted a multicenter Phase II trial of imatinib in patients with relapsed or refractory KIT-positive (excluding GISTs) or PDGFR-positive sarcomas.
Methods
Patient ages ranged from 12 and 75 years. Eligibility criteria included (1) metastatic sarcomas with a definitive diagnosis based on histopathology or that were completely unresectable and locally advanced; (2) relapsed or refractory cases that had completed standard treatment; and (3) a tumor confirmed by immunohistochemical staining to be KIT- or PDGFR-positive. A 600-mg dose of imatinib was administered to patients once a day, with each patient receiving six courses of the drug and each course lasting 4 weeks. In cases categorized as stable or progressive, the imatinib dose was increased to 800 mg/day administered twice daily.
Results
A total of 25 patients who met the eligibility criteria were enrolled in the trial; 22 were evaluated for response. The response rate with a 600 mg/day dose of imatinib was 4.5% (0 complete response, 1 partial response). There were no other objective responses after increasing imatinib to 800 mg/day (0/10). We estimated 50% progression-free survival to be 61.0 days for an imatinib dose of 600 mg/day based on the Kaplan-Meier method. Side effects of imatinib were generally similar to those observed in previous clinical trials.
Conclusions
Our results did not indicate effectiveness of imatinib monotherapy at a dose of 600 or 800 mg/day in patients with relapsed or refractory KIT-positive (excluding GISTs) or PDGFR-positive sarcomas. Our findings suggest the need to evaluate the synergistic effect of combination therapy with other anticancer drugs.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: implications for decision making in the clinic. Hematol Oncol Clin North Am 1995;9:765–785.
Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25:3144–3150.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–566.
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 2002;347:472–480.
Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586–3591.
Tamborini E, Bonadiman L, Greco A, Gronchi A, Riva C, Bertulli R, et al. Expression of ligand-activated KIT and platelet derived growth factor receptor beta tyrosine kinase receptor in synovial sarcoma. Clin Cancer Res 2004;10:938–943.
Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 2002;26:486–492.
Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC. Expression of stem cell factor and c-kit in human neuroblastoma: the Children’s Cancer Group. Blood 1994;84:3465–3472.
González I, Andreu EJ, Panizo A, Inogés S, Fontalba A, Fernández-Luna JL, et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004;10:751–761.
Sulzbacher I, Träxler M, Mosberger I, Lang S, Chott A. Plateletderived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 2000;13:632–637.
Abdiu A, Wingren S, Larsson SE, Wasteson A, Walz TM. Effects of human platelet-derived growth factor-AB on sarcoma growth in vitro and vivo. Cancer Lett 1999;141:39–45.
Oda Y, Wehrmann B, Radig K, Walter H, Röse I, Neumann W, et al. Expression of growth factors and their receptors in human osteosarcomas: immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. Gen Diagn Pathol 1995;141:97–103.
Sulzbacher I, Birner P, Trieb K, Träxler M, Lang S, Chott A. Expression of platelet derived growth factor AA is associated with tumor progression in osteosarcoma. Mod Pathol 2003;16:66–71.
Froberg K, Brown RE, Gaylord H, Manivel C. Intraabdominal desmoplastic small round cell tumor: immunohistochemical evidence for up-regulation of autocrine and paracrine growth factors. Ann Clin Lab Sci 1999;29:78–85.
Lee SB, Kolquist KA, Nichols K, Englert C, Maheswaran S, Ladanyi M, et al. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round cell tumors. Nat Genet 1997;17:309–313.
Zhang PJ, Goldblum JR, Pawel BR, Pasha TL, Fisher C, Barr FG. PDGF-A, PDGFR beta, TGFbeta3 and bone morphogenic protein 4 in desmoplastic small round cell tumors with EWS-WT1 gene fusion product and their role in stromal dysplasia: an immunohistochemical study. Mod Pathol 2005;18:382–387.
Palman C, Bowen-Pope DF, Brooks JJ. Platelet derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors. Lab Invest 1992;66:108–115.
Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing’s sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673–1679.
Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ. Effect of Imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004;96:46–55.
Enforcement Regulation No.106 of the Ministry of Health, Labor, and Welfare (revised GCP) dated May 15, 2003 (in Japanese).
The revised Pharmaceutical Affairs Act (“Kaisei Yakuji-hou”) No. 96 of the Ministry of Health, Labor, and Welfare dated July 31, 2002 (in Japanese).
Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, et al. A Phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer 2008;50:254–258.
Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Myers PA, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J Clin Oncol 2009;27:3148–3153.
Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14:2717–2725.
Ugurel S, Hildenbrand R, Zimpfer A, La Rosée P, Paschka P, Sucker A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398–1405.
Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial. Cancer 2005;103:2128–2131.
Modi S, Seidman AD, Dickler M, Moasser M, D’Andrea G, Moynahan ME, et al. A Phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2005;90:157–163.
Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, et al. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer 2006;106:366–374.
Author information
Authors and Affiliations
About this article
Cite this article
Sugiura, H., Fujiwara, Y., Ando, M. et al. Multicenter Phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci 15, 654–660 (2010). https://doi.org/10.1007/s00776-010-1506-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00776-010-1506-9